Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-Propafenone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
(S)-Propafenone is the S-enantiomer of propafenone, a Class IC antiarrhythmic medication used to treat cardiac arrhythmias. It works by slowing the influx of sodium ions into cardiac muscle cells, decreasing their excitability. The S-enantiomer has equivalent sodium channel blocking potency to the R-enantiomer but is a more potent beta-adrenergic antagonist. Propafenone is primarily used to treat paroxysmal atrial fibrillation/flutter and life-threatening ventricular arrhythmias such as sustained ventricular tachycardia in patients without structural heart disease.
- Other names
- (S)-SA-79PropafenonaPropafenonum
02
Targets
ADRB1 (β1)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on (S)-Propafenone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (S)-Propafenone.